{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:06:30Z","timestamp":1793862390384,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dual point-of-care tests (POCTs) for the simultaneous detection of antibodies to HIV and syphilis have been developed. Since community-based organisations (CBO) are effective providers of HIV and syphilis testing among men who have sex with men (MSM), evaluation of the utility of these dual tests at CBO testing services is a high priority. The aim of this study is to determine the feasibility of performing dual HIV-syphilis POCT testing among both users and providers at these non-clinical sites.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This evaluation assessed the utility of two lateral flow immunochromatographic antibody technologies for dual screening for HIV\/syphilis among MSM seeking testing in four CBO testing services in Spain, Slovenia, Latvia, and Ukraine. The study\u2019s conceptual framework divides the concept of feasibility into two inter-related domains, acceptability, and usability and further breaks it down into six subdomains: learnability, willingness, suitability, satisfaction, efficacy, and effectiveness. The feasibility analysis was performed by calculating the median score in 3 stages (for individual questions, subdomains, and domains), using a summated scores method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The final sample included 844 participants, 60 of which were found to be HIV test positive (7.1%) and 61 (7.2%) positive on testing for syphilis. There was a small difference (1.1%) when comparing the results of the two dual POCTs under evaluation to the tests routinely used at each site. The inter-rater agreement showed a high concordance between two independent readings. The analysis of the feasibility for the users of the services indicated good satisfaction, suitability, and willingness. In addition, among 18 providers the total mean score showed good acceptability and usability, good willingness, easy learnability, high suitability, and good efficacy, but lower satisfaction and effectiveness. The operational characteristics of both dual study POCTs were well evaluated by providers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The introduction of dual HIV and syphilis\u00a0 POCTs in CBO testing services for screening of MSM is feasible, with a high acceptability and usability both for users and providers. Implementation of dual POCTs for HIV and syphilis in CBO testing services is an opportunity for scaling up integrated HIV\/syphilis testing for MSM.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09017-5","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:02:47Z","timestamp":1709164967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A clinical utility evaluation of dual HIV\/Syphilis point-of-care tests in non-clinical settings for screening for HIV and syphilis in men who have sex with men"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6353-3942","authenticated-orcid":false,"given":"Laura","family":"Fern\u00e0ndez-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Reyes-Urue\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Egea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrii","family":"Chernyshev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Upmace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitja","family":"\u0106osi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mej\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Blondeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soe Soe","family":"Thwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mirandola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Peeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kiarie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Casabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Toskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ProSPeRo group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"9017_CR1","unstructured":"ECDC, WHO. HIV\/AIDS surveillance in Europe 2021. 2020 data. 2021."},{"key":"9017_CR2","unstructured":"ECDC. Syphilis Annual Epidemiological Report for 2018 [Internet]. 2019 [cited 2021 Feb 22]. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/syphilis-aer-2018.pdf"},{"key":"9017_CR3","doi-asserted-by":"crossref","unstructured":"Toskin I, Govender V, Blondeel K, Murtagh M, Unemo M, Zemouri C, et al. Call to action for health systems integration of point-of-care testing to mitigate the transmission and burden of sexually transmitted infections. Sex Transm Infect. 2020;96(5):342\u20137.","DOI":"10.1136\/sextrans-2019-054358"},{"key":"9017_CR4","doi-asserted-by":"crossref","unstructured":"Smith MK, Rutstein SE, Powers KA, Fidler S, Miller WC, Eron JJ, et al. The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr. 2013;63(SUPPL. 2). [cited 2021 May 20]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23764635\/","DOI":"10.1097\/QAI.0b013e31829871e0"},{"key":"9017_CR5","doi-asserted-by":"crossref","unstructured":"Rutstein SE, Ananworanich J, Fidler S, Johnson C, Sanders EJ, Sued O, et al. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review: A. J Int AIDS Soc. 2017;20(1). [cited 2021 May 20]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28691435\/","DOI":"10.7448\/IAS.20.1.21579"},{"issue":"S4","key":"9017_CR6","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1136\/sextrans-2016-053073","volume":"93","author":"I Toskin","year":"2017","unstructured":"Toskin I, Blondeel K, Peeling RW, Deal C, Kiarie J. Advancing point of care diagnostics for the control and prevention of STIs: the way forward. Sex Transm Infect. 2017;93(S4):S81-8. [cited 2019 Apr 15]. Available from: https:\/\/sti.bmj.com\/content\/93\/S4\/S81.","journal-title":"Sex Transm Infect."},{"issue":"8","key":"9017_CR7","doi-asserted-by":"publisher","first-page":"e1001496","DOI":"10.1371\/journal.pmed.1001496","volume":"10","author":"AB Suthar","year":"2013","unstructured":"Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10(8):e1001496. [cited 2014 Oct 23]. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3742447&tool=pmcentrez&rendertype=abstract.","journal-title":"PLoS Med."},{"issue":"2","key":"9017_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1108\/JHR-01-2018-015","volume":"32","author":"JS Sulat","year":"2018","unstructured":"Sulat JS, Prabandari YS, Sanusi R, Hapsari ED, Santoso B. The impacts of community-based HIV testing and counselling on testing uptake. J Heal Res. 2018;32(2):152\u201363. [cited 2019 May 23]. Available from:https:\/\/www.emeraldinsight.com\/doi\/10.1108\/JHR-01-2018-015.","journal-title":"J Heal Res."},{"issue":"12","key":"9017_CR9","doi-asserted-by":"publisher","first-page":"e006859","DOI":"10.1136\/bmjopen-2014-006859","volume":"4","author":"K Pottie","year":"2014","unstructured":"Pottie K, Medu O, Welch V, Dahal GP, Tyndall M, Rader T, et al. Effect of rapid HIV testing on HIV incidence and services in populations at high risk for HIV exposure: an equity-focused systematic review. BMJ Open. 2014;4(12):e006859. [cited 2016 Feb 24]. Available from:http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4267075&tool=pmcentrez&rendertype=abstract.","journal-title":"BMJ Open."},{"key":"9017_CR10","unstructured":"World Health Organization. Consolidated guidelines on HIV testing services: 5Cs: consent, confidentiality, counselling, correct results and connection. Geneva; 2015 [cited 2018 Oct 30]. Available from: http:\/\/www.who.int\/hiv\/pub\/vct\/hiv-self-testing-guidelines\/en\/"},{"key":"9017_CR11","unstructured":"World Health Organization. Country policy adoption of dual HIV-syphilis tests in antenatal care 2021.png (4961\u00d73508). 2022 [cited 2023 May 19]. Available from: https:\/\/www.who.int\/images\/default-source\/departments\/hiv\/country-policy-adoption-of-dual-hiv-syphilis-tests-in-antenatal-care-2021.png?sfvrsn=3fa9e605_4"},{"issue":"8","key":"9017_CR12","doi-asserted-by":"publisher","first-page":"e056887","DOI":"10.1136\/bmjopen-2021-056887","volume":"12","author":"D Coomes","year":"2022","unstructured":"Coomes D, Green D, Barnabas R, Sharma M, Barr-Dichiara M, Jamil MS, et al. Cost-effectiveness of implementing HIV and HIV\/syphilis dual testing among key populations in Viet Nam: a modelling analysis. BMJ Open. 2022;12(8):e056887. [cited 2023 May 19]. Available from: https:\/\/bmjopen.bmj.com\/content\/12\/8\/e056887.","journal-title":"BMJ Open."},{"key":"9017_CR13","unstructured":"Chembio diagnostics receives FDA approval for DPP HIV-syphilis system \u2013 Chembio Diagnostics, Inc. 2020 [cited 2023 May 29]. Available from: https:\/\/chembio.com\/chembio-diagnostics-receives-fda-approval-for-dpp-hiv-syphilis-system\/"},{"key":"9017_CR14","unstructured":"WHO. Prequalification of in vitro diagnostics programme, public report. Geneva; 2017. [cited 2021 Feb 9]. Available from: https:\/\/www.who.int\/diagnostics_laboratory\/evaluations\/151028_final_report_0179-012-00_sd_bioline_hiv_syphilis2.pdf?ua=1"},{"key":"9017_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/sextrans-2017-053099","volume":"93","author":"HD Gliddon","year":"2017","unstructured":"Gliddon HD, Peeling RW, Kamb ML, Toskin I, Wi TE, Taylor MM. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex Transm Infect. 2017;93:3\u201315. [cited 2019 Apr 15]. Available from:http:\/\/sti.bmj.com\/.","journal-title":"Sex Transm Infect."},{"key":"9017_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/819593","volume":"2013","author":"J Bergman","year":"2013","unstructured":"Bergman J, Gratrix J, Plitt S, Fenton J, Archibald C, Wong T, et al. Feasibility and field performance of a simultaneous syphilis and HIV point-of-care test based screening strategy in at risk populations in Edmonton, Canada. AIDS Res Treat. 2013;2013:1\u20138.","journal-title":"AIDS Res Treat"},{"issue":"1","key":"9017_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1748-5908-7-5","volume":"7","author":"C Asiimwe","year":"2012","unstructured":"Asiimwe C, Kyabayinze DJ, Kyalisiima Z, Nabakooza J, Bajabaite M, Counihan H, et al. Early experiences on the feasibility, acceptability, and use of malaria rapid diagnostic tests at peripheral health centres in Uganda-insights into some barriers and facilitators. Implement Sci. 2012;7(1):5. [cited 2020 Mar 5]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22269037.","journal-title":"Implement Sci."},{"key":"9017_CR18","unstructured":"World Health Organization (WHO) HRP. Utility evaluation of point-of-care tests in non-clinical settings for the screening of HIV and syphilis in men who have sex with men. [cited 2022 Mar 30]. Available from: https:\/\/www.who.int\/reproductivehealth\/topics\/rtis\/Core-Protocol-Utility-Evaluation-POCT-HIV-syph-MSM.pdf?ua=1"},{"key":"9017_CR19","doi-asserted-by":"publisher","unstructured":"The ProSPeRo Network. Standardised protocol for a prospective cross-sectional multicentre clinical utility evaluation of two dual point-of-care tests in non-clinical settings for the screening of HIV and syphilis in men who have sex with men. BMJ Open. 2022;12(6). https:\/\/doi.org\/10.1136\/bmjopen-2021-055275. [cited 2022 Sep 9].","DOI":"10.1136\/bmjopen-2021-055275"},{"key":"9017_CR20","unstructured":"WHO. Summary of prequalification status for Bioline HIV\/Syphilis duo date outcome status on PQ list."},{"key":"9017_CR21","unstructured":"Product: DPP\u00ae HIV 1\/2 Assay WHO reference number: PQDx 0053\u2013006\u201300."},{"key":"9017_CR22","unstructured":"FDA, CBER. Indications For Use - DPP HIV-Syphilis System [Internet]. 2020 [cited 2021 Feb 9]. Available from: https:\/\/www.fda.gov\/media\/142615\/download"},{"issue":"S4","key":"9017_CR23","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1136\/sextrans-2016-053065","volume":"93","author":"A Zorzi","year":"2017","unstructured":"Zorzi A, Cordioli M, Gios L, Del Bravo P, Toskin I, Peeling RW, et al. Field evaluation of two point-of-care tests for syphilis among men who have sex with men, Verona. Italy Sex Transm Infect. 2017;93(S4):S51-8. [cited 2021 Feb 9]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29223963\/","journal-title":"Italy. Sex Transm Infect."},{"key":"9017_CR24","doi-asserted-by":"publisher","unstructured":"Cao W, Fakile YF, Shukla MR, Pettus K, Lupoli K, Hong J, Pillay A, Kularatne R, Oumzil H, Padovese V, Sherriff N, SSewanyana I, Vargas SK, Zorzi A, Blondeel K, Toskin I, Kersh EN. External quality assessment to support the WHO ProSPeRo study for the evaluation of two dual HIV\/syphilis point-of-care tests in seven countries. BMC Infect Dis. 2024;24 (supplement 1). https:\/\/doi.org\/10.1186\/s12879-024-09027-3.","DOI":"10.1186\/s12879-024-09027-3"},{"key":"9017_CR25","unstructured":"Robbins NB, Heiberger RM. Plotting likert and other rating scales. Jt Stat Meet. 2011;1058\u201366. [cited 2020 Apr 14]. Available from: http:\/\/www.amstat.org\/sections\/srms\/proceedings\/y2011\/Files\/300784_64164.pdf"},{"issue":"6","key":"9017_CR26","first-page":"455","volume":"40","author":"HG Gait\u00e1n-Duarte","year":"2016","unstructured":"Gait\u00e1n-Duarte HG, Newman L, Laverty M, Abu Habib N, Gonz\u00e1lez-Gordon LM, \u00c1ngel-M\u00fcller E, et al. Comparative effectiveness of single and dual rapid diagnostic tests for syphilis and HIV in antenatal care services in Colombia - PubMed. Rev Panam Salud Publica. 2016;40(6):455\u201361. [cited 2021 Mar 5]. Available from:https:\/\/pubmed.ncbi.nlm.nih.gov\/28718495\/.","journal-title":"Rev Panam Salud Publica."},{"key":"9017_CR27","doi-asserted-by":"crossref","unstructured":"Olugbenga I, Taiwo O, Laverty M, Ngige E, Anyaike C, Bakare R, et al. Clinic-based evaluation study of the diagnostic accuracy of a dual rapid test for the screening of HIV and syphilis in pregnant women in Nigeria. PLoS One. 2018;13(7):e0198698. [cited 2021 Mar 8]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6038984\/.","DOI":"10.1371\/journal.pone.0198698"},{"key":"9017_CR28","doi-asserted-by":"crossref","unstructured":"Zalazar V, Frola CE, Gun A, Radusky PD, Panis NK, Cardozo NF, et al. Acceptability of dual HIV\/syphilis rapid test in community- and home-based testing strategy among transgender women in Buenos Aires, Argentina. Int J STD AIDS. 2021;956462420979852. [cited 2021 Mar 4]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33533303\/","DOI":"10.1177\/0956462420979852"},{"issue":"4","key":"9017_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02726504","volume":"19","author":"PS Ellen","year":"1991","unstructured":"Ellen PS, Bearden WO, Sharma S. Resistance to technological innovations: An examination of the role of self-efficacy and performance satisfaction. J Acad Mark Sci. 1991;19(4):297\u2013307. [cited 2021 Mar 2]. Available from: https:\/\/link.springer.com\/article\/10.1007\/BF02726504.","journal-title":"J Acad Mark Sci."},{"issue":"4","key":"9017_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4300\/JGME-5-4-18","volume":"5","author":"GM Sullivan","year":"2013","unstructured":"Sullivan GM, Artino AR Jr. Analyzing and Interpreting data from likert-type scales. J Grad Med Educ. 2013;5(4):541 [cited 2022 Apr 8]. Available from: \/pmc\/articles\/PMC3886444\/.","journal-title":"J Grad Med Educ."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09017-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09017-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09017-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:03:32Z","timestamp":1709165012000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09017-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":30,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["9017"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09017-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been independently peer reviewed and approved by the Research Project Review Panel (RP2) of the WHO Department of Sexual and Reproductive Health and Research (SRH) and by the WHO Ethics Review Committee (ERC), and by ethics committees in each country. Autonomy of the users to decide to participate in the study was safeguarded by the division of the roles of taking pre-consent on the one hand and performing the study on the other. The final consent was taken by the CBO testing service provider who performs the test, as they also checked if the user met the inclusion criteria, for confidentiality reasons.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The POCT manufacturers furnished sufficient quantities of the product(s) free of charge in order to enable this evaluation as part of the WHO\/RHR STI POC initiative. WHO is entitled to evaluate and publish the trial results, and to exclusively control this evaluation and the content of the publication. WHO shall submit any proposed publication to the manufacturers for review, comments received will be considered in good faith, but the decision to publish rests with WHO.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}